Incyte has received European Commission approval for Zynyz (retifanlimab) in combination with carboplatin and paclitaxel as a ...

Chief Executive Officer Sean A MacDonald added: “The successful completion of this Phase I study represents an important step for Kainova Therapeutics, highlighting the strength of our innovative ...

Astellas Pharma has announced that the National Institute for Health and Care Excellence has issued Final Draft Guidance recommending fezolinetant 45 mg once daily for treating moderate to severe ...

UCB has announced positive topline results from its BE BOLD trial, the first head‑to‑head study in active psoriatic arthritis to demonstrate superiority of one licensed biologic therapy over an IL‑23 ...

Aplagon has dosed the first patient in its phase 2a HEALING clinical trial evaluating APAC, a first‑in‑class treatment for thrombo‑inflammatory diseases, in people with peripheral arterial occlusive ...

The MHRA has approved deuruxolitinib, marketed as Leqselvi, for the treatment of severe alopecia areata in adults, offering a new therapeutic option for people living with the autoimmune condition.

Professor Günter Höglinger, Lead Investigator of the Mascot trial, said: “Completing randomization of a global Phase 3 trial in MSA is a significant achievement for the field.” He added: “Advancing ...

EnteroBiotix has completed enrolment for its investigator‑initiated phase 2a MAST trial, which is evaluating the company’s microbiome therapy EBX‑102‑02 in adults undergoing allogeneic haematopoietic ...